Project Grant R16GM153544
Award Date 8/1/25
Completion Date 7/31/29
Dollars Obligated $146K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Jackson, MS 39217, USA
Similar Awards
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $406,611 to the University of Texas Health Science Center at Houston (UTHealth) to identify the role and signaling mechanisms of the GPR56 protein in colorectal cancer progression and therapy resistance. The project aims to develop and evaluate novel antibody-drug conjugates and combination therapies targeting GPR56 for the improved treatment of colorectal cancer. Key activities...
- This federal Project Grant award of $205,700 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research at the Sloan-Kettering Institute for Cancer Research in New York aimed at understanding and overcoming rapid resistance to targeted therapies in colorectal cancer. The key objectives are to evaluate how intrinsic tumor features modulate the development of resistance to targeted therapies, and to test a novel combination approach to...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will support the development of a "Spatial Profiling-Based Immune Hub Perturbation Platform" to improve immunotherapy for colorectal cancer. The $710,361 award to J. David Gladstone Institutes will fund research to create a novel experimental framework to systematically test and prioritize candidate genes and therapies based on their ability to induce effective anti-tumor immune hubs -...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) provides $154,642 to the Sloan-Kettering Institute for Cancer Research in New York to conduct research on identifying conserved cancer-specific immunopeptide targets in metastatic colorectal cancer. The project aims to systematically elucidate the evolving immunopeptidome (peptides presented by HLA class I molecules) from patient-derived colorectal cancer organoids to reveal targetable...
- This $546,625 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to conduct research on targeting the irhom protein to improve colon cancer immunotherapy. The grant was awarded to the University of Pittsburgh, a prominent public research university, on January 9, 2025, with a planned completion date of December 31, 2029. The key objectives of this project are to explore the role of irhom proteins, particularly irhom1, in regulating...
- This $284,201.82 Project Grant from the National Cancer Institute, a division of the Department of Health and Human Services, will fund research into malignant cell engagement in immune circuits of human colorectal cancer. The Broad Institute, Inc. will utilize single cell RNA sequencing data from over 700,000 malignant, immune, and stromal cells from colorectal cancer patients to test the hypothesis that malignant cells expressing interferon-stimulated genes acutely promote anti-tumor immunity,...
- This federal Project Grant award of $423,084 was provided by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to support research on the musculoskeletal cost of metastatic colorectal cancer. The award aims to identify targetable mediators of skeletal muscle and bone loss in advanced colorectal cancer, with a focus on the role of the hormone FGF21. The research is being conducted by the Trustees of Indiana University at Indiana University Indianapolis from May 2025 through...
- This $192,888 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports a research project at the University of Virginia (UVA) to investigate the use of normal colon organoids for identifying causal genetic variants associated with colorectal cancer risk. The key objectives of the project are to: 1) test the hypothesis that colorectal cancer GWAS genes are cell type-specific, and 2) determine the role of these genes within colon epithelial...
- This $640,583 federal Project Grant was awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Cold Spring Harbor Laboratory to conduct research aimed at enhancing the efficacy of immunotherapy against metastatic colorectal cancer. The primary goal is to activate the PPARD-CPT1A axis in CD8+ T cells to boost their anti-tumor immunity and improve treatment outcomes for patients with microsatellite stable metastatic colorectal cancer, who typically respond poorly...
- This $2,864,671 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Regents of the University of Michigan is focused on developing a novel strategy to enzymatically inhibit colibactin, a procarcinogenic metabolite from enteric bacteria associated with colorectal cancer (CRC). The objectives are to: (1) create engineered microbes that can deliver the colibactin inactivation protein ClbS to safely and effectively neutralize colibactin in the gut,...